Akal College of Pharmacy and Technical Education, Sangrur, Punjab, India.
Department of Pharmaceutics, Vishwabharathi College of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India.
J Biomater Sci Polym Ed. 2021 Mar;32(4):477-487. doi: 10.1080/09205063.2020.1844506. Epub 2020 Nov 23.
Nitazoxanide (NTZ) is a synthetic form of nitrothiazole with a broad range of applications as an antiparasitic, antibacterial and antiviral agent. NTZ is a highly low aqueous soluble drug which possesses solubility of 0.00755 mg/mL and typically low bioavailability of 1%. Low aqueous solubility is usually regarded as prime prerequisites for enhanced absorption and bioavailability. The purpose of this study is to improve dissolution of the poorly soluble drug NTZ through amorphous solid dispersion technology. Three solid dispersions of NTZ were successfully prepared by hot-melt technique. It was further evaluated for drug content, DSC, XRD, SEM, TEM, FT-IR, in-vitro drug release study, MTT safety on HEK-293 and A-549 and stability study. The results of XRD showed after the formation of solid dispersions. The number of crystalline peaks has disappeared and confirmed the amorphous form of the drug. An release study showed that NTZ effectively released from solid dispersion into a simulated gastric releasing medium (pH 1.2). Further, the cytotoxicity study gave an indication of safe for human. Also, stability studies depicted no evident difference in the physical state of solid dispersion after six months. Hence, it can be concluded that the newly developed formulation was found to be safe and stable with enhanced solubility profile.
硝唑尼特(NTZ)是一种具有广泛应用的硝基噻唑类合成物,可用作抗寄生虫药、抗菌药和抗病毒药。NTZ 是一种水溶性很差的药物,其在水中的溶解度为 0.00755mg/mL,生物利用度通常很低,只有 1%。水溶性低通常被认为是提高药物吸收和生物利用度的首要前提。本研究旨在通过无定形固体分散技术提高难溶性药物 NTZ 的溶解度。采用热熔法成功制备了 3 种 NTZ 固体分散体。进一步对其进行了药物含量、差示扫描量热法(DSC)、X 射线衍射(XRD)、扫描电子显微镜(SEM)、透射电子显微镜(TEM)、傅里叶变换红外光谱(FT-IR)、体外药物释放研究、MTT 安全性(对 HEK-293 和 A-549 的安全性)和稳定性研究。XRD 结果表明,固体分散体形成后,结晶峰的数量消失,证实了药物的无定形形式。释放研究表明,NTZ 能从固体分散体中有效释放到模拟胃液释放介质(pH 1.2)中。此外,细胞毒性研究表明,该制剂对人体安全。稳定性研究表明,在 6 个月后,固体分散体的物理状态没有明显变化。因此,可以得出结论,新开发的制剂具有良好的稳定性和安全性,同时溶解度也得到了提高。